Plandai Biotech Stock Key Fundamental Indicators
| PLPL Stock | USD 0.0001 0.00 0.00% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plandai Biotech, as well as the relationship between them.
Plandai Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Plandai Biotech's valuation are provided below:Plandai Biotech does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Plandai |
Plandai Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Plandai Biotech's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Plandai Biotech.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Plandai Biotech on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Plandai Biotech or generate 0.0% return on investment in Plandai Biotech over 90 days. Plandai Biotech is related to or competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmac... More
Plandai Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Plandai Biotech's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Plandai Biotech upside and downside potential and time the market with a certain degree of confidence.
Plandai Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plandai Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Plandai Biotech's standard deviation. In reality, there are many statistical measures that can use Plandai Biotech historical prices to predict the future Plandai Biotech's volatility.Plandai Biotech Backtested Returns
Plandai Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.16, which implies the firm had a 0.16 % return per unit of risk over the last 3 months. We were able to interpolate data for three different technical indicators, which can help you to evaluate if expected returns of 30.0% are justified by taking the suggested risk. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Plandai Biotech are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Plandai Biotech has no correlation between past and present. Overlapping area represents the amount of predictability between Plandai Biotech time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Plandai Biotech price movement. The serial correlation of 0.0 indicates that just 0.0% of current Plandai Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.91 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Plandai Biotech has a Return On Asset of -0.2096. This is 55.4% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The return on asset for all United States stocks is 49.71% higher than that of the company.
Plandai Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Plandai Biotech's current stock value. Our valuation model uses many indicators to compare Plandai Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Plandai Biotech competition to find correlations between indicators driving Plandai Biotech's intrinsic value. More Info.Plandai Biotech is rated below average in return on asset category among its peers. It also is rated below average in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Plandai Biotech's earnings, one of the primary drivers of an investment's value.Plandai Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Plandai Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Plandai Biotech could also be used in its relative valuation, which is a method of valuing Plandai Biotech by comparing valuation metrics of similar companies.Plandai Biotech is currently under evaluation in return on asset category among its peers.
Plandai Fundamentals
| Return On Asset | -0.21 | |||
| Operating Margin | (12.22) % | |||
| Current Valuation | 236.87 K | |||
| Shares Outstanding | 263.19 M | |||
| Price To Earning | (0.32) X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 411.99 K | |||
| Gross Profit | (768.91 K) | |||
| EBITDA | (2.1 M) | |||
| Net Income | (4.01 M) | |||
| Cash And Equivalents | 7.96 K | |||
| Total Debt | 50.53 K | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 0.01 X | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (1.1 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 250 | |||
| Beta | -1.3 | |||
| Market Capitalization | 276.35 K | |||
| Total Asset | 6.82 M | |||
| Retained Earnings | (39.32 M) | |||
| Working Capital | (15.26 M) | |||
| Current Asset | 176 K | |||
| Current Liabilities | 15.44 M | |||
| Z Score | -6.4 | |||
| Net Asset | 6.82 M |
About Plandai Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Plandai Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Plandai Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Plandai Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Planda Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. Planda Biotechnology, Inc. is based in London, the United Kingdom. Diamond Ranch is traded on OTC Exchange in the United States.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Plandai Pink Sheet
Plandai Biotech financial ratios help investors to determine whether Plandai Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Plandai with respect to the benefits of owning Plandai Biotech security.